Drug intelligence / Profile preview

sacubitril + valsartan (Easywell Biomedical)

Development stage: Phase 4
Lead developer: Easywell Biomedicals
Modality: Small Molecules
Administration: Oral

Overview

HH-001 is Jiangsu Huahan Pharmaceutical's China-marketed oral fixed-dose tablet of **sacubitril + valsartan**, marketed as **悅心妥**. It is an angiotensin receptor-neprilysin inhibitor: sacubitril is converted to LBQ657, which inhibits neprilysin and increases natriuretic-peptide activity, while valsartan blocks the angiotensin II type 1 receptor to suppress maladaptive renin-angiotensin-aldosterone-system signaling. Easywell Biomedical reported that the product received China NMPA drug certification in October 2023 and was launched in mainland China in 2024 for chronic heart failure. ([easywellbio.com](https://www.easywellbio.com/en/news_view.php?id=228))

Brand names: 悅心妥
Other names: Sacubitril/Valsartan Sodium Tabletssacubitril/valsartan沙庫巴曲纈沙坦鈉片沙库巴曲缬沙坦钠片

Targets

AGTR1 (Angiotensin II Type-1 receptor)NEP (Neutral Endopeptidase)

Beyond the preview

Go deeper on sacubitril + valsartan (Easywell Biomedical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sacubitril + valsartan (Easywell Biomedical).